SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in EGFR-mutated lung cancer, citing the lack of statistically significant overall-survival benefit despite a strong progression-free-survival result; the decision has prompted bearish selling and debate over a possible appeal. Some traders view the setback as limited to this indication and point to future HARMONi-3 data and the broader pipeline, while others question the near-term outlook.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharmas anticipated Phase 3 APPROACH topline results for HLP003 in major depressive disorder dominate discussion, with traders treating the readout as a binary catalyst. Optimists point to its adjunctive design and potential for shorter clinic sessions, while skeptics flag the risk that Phase 2 efficacy may not replicate, alongside dilution and competitive concerns.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol Myers quarterly results, which beat expectations and came with a higher revenue outlook, are drawing attention; the lower earnings outlook tied to licensing charges and concerns about replacing legacy-drug sales have tempered some bullish reactions.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is drawing attention over a nationwide FAA communications outage that officials and reports have linked to its network, with investigators still determining whether equipment or installation problems were responsible. Traders are debating potential liability and contract fallout versus claims the company is being scapegoated, while some view the selloff as a buying opportunity.

Select Sector SPDR Trust (The) - State Street Consumer Staples Select Sector SPDR ETF

Consumer Staples Select Sector SPDR Fund

XLP is drawing attention as money rotates out of tech and into consumer staples amid defensive positioning, with traders highlighting the sectors sharp rally and fresh highs. Some see pullbacks as buying opportunities, while others warn the move is crowded, overbought, and supported by stretched valuations.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid persistent selling and volatile, weak price action, with traders divided between buying the dip and warning of further declines. Bulls point to Stellars DTCC and real-world-asset tokenization prospects, while skeptics argue that institutional activity has yet to translate into stronger token performance.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

A strong Q3 results beat and raised 2026 revenue outlook have driven attention, with traders highlighting HEPZATO growth and expansion across hospital systems. The reaction is broadly upbeat, though some are cautious about the sharp run-up and whether site adoption and treatment volumes can sustain it.

Autonomi (ANT) is a cryptocurrency launched in 2025and operates on the Arbitrum platform. Autonomi has a current supply of 1,200,000,000 with 346,331,579 in circulation. The last known price of Autonomi is 0.03106712 USD and is down -0.55 over the last 24 hours. It is currently trading on 15 active market(s) with $122,300.99 traded over the last 24 hours. More information can be found at https://autonomi.com.

Aragon

Attention is largely driven by ticker confusion with Anthropics widely discussed IPO, with many posts using Aragons $ANT.X tag for the AI company. Aragon-specific comments instead focus on the projects dissolution, the completed token redemption, and concerns about exchange delisting; no single new market catalyst for the crypto is established.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTechs positive Phase 2 results for its HER2-targeted drug trastuzumab pamirtecan in recurrent endometrial cancer are drawing attention to its oncology pipeline. Traders are reacting optimistically to the clinical progress, while broader concerns about execution and leadership remain part of the debate.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

UEC is drawing attention amid a sharp selloff and debate over its latest results: bearish traders point to losses, inconsistent revenue and softer uranium prices, while bulls argue its production ramp, cash-rich balance sheet and long-term nuclear-fuel demand support the investment case. The discussion is split between continued downside concerns and dip-buying around the uranium sectors longer-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Golden Star Resources Ltd. engages in gold mining and exploration activities. It owns and operates the Wassa and Prestea mines situated in Ghana. The firm also operates through the following segments: Wassa, Bogoso or Prestea, Other, and Corporate. The company was founded by David A. Fennell on May 15, 1992 and is headquartered in Toronto, Canada.

Golden Star Resources Ltd.

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

About GSS